Resistance training may curb lean mass loss with tirzepatide - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Resistance training may curb lean mass loss with tirzepatide

  • By

  • Andrea Surnit

  • November 20, 2026

  • 5 min

Share

Clinical Scorecard: Resistance training may curb lean mass loss with tirzepatide

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Resistance training may curb lean mass loss with tirzepatide
Key MechanismsIn a 40-week trial, supervised resistance exercise reduced loss of DXA-measured lean soft tissue mass and improved bench press, lat pulldown, and knee extension strength during tirzepatide treatment; weight and fat loss were similar between groups.
Target PopulationPatients or participants described in the source article.
Care SettingCare setting described in the source article.

Key Highlights

  • At week 40, total lean soft tissue mass loss was 3.57 kg with resistance exercise plus tirzepatide and 4.67 kg with tirzepatide alone; the between-group difference was 1.09 kg.
  • Appendicular lean soft tissue mass loss was 0.63 kg lower with resistance exercise than with tirzepatide alone.
  • Bench press, lat pulldown, and knee extension strength increased in the exercise group and declined in the tirzepatide-only group; all between-group differences were statistically significant.
  • Weight loss, fat mass loss, BMI, waist circumference, and measured cardiometabolic changes were similar between groups.
  • The trial enrolled 120 participants; 93% completed 40 weeks, and mean adherence to supervised exercise sessions was 91%.

Guideline-Based Recommendations

Diagnosis

    Management

    • Study authors stated that resistance exercise training should be considered when prescribing incretin mimetics as anti-obesity therapy.
    • The tested intervention was progressive, supervised resistance training for approximately 1 hour, 3 times weekly, alongside tirzepatide for 40 weeks.

    Monitoring & Follow-up

      Risks

      • Gastrointestinal adverse events were common in both groups; nausea occurred in 55% of participants, and constipation, diarrhea, and indigestion were reported in approximately 29% to 36%.
      • Six serious adverse events occurred; the authors considered none related to tirzepatide or resistance exercise.
      • The study used DXA measures of lean soft tissue mass, not direct measures of skeletal muscle mass, and did not establish long-term clinical outcomes.

      Patient & Prescribing Data

      The T-REx trial included 120 initially sedentary men and postmenopausal women aged 50 to 70 years with obesity or overweight plus at least one weight-related comorbidity. Participants did not have diabetes or cardiovascular disease.

      Participants received tirzepatide for 40 weeks, titrated to a maximum of 15 mg weekly as tolerated; 61 were assigned to tirzepatide alone and 59 to tirzepatide plus supervised resistance exercise. Among 111 treatment completers, 78 received the maximum dose.

      Clinical Best Practices

      • When discussing the trial, distinguish lean soft tissue mass measured by DXA from skeletal muscle mass.
      • Explain that resistance exercise was associated with less lean soft tissue mass loss and greater measured strength, while weight and fat loss were comparable between groups.
      • Consider the trial's limits when applying its findings: participants were initially sedentary, the exercise was closely supervised, and follow-up lasted 40 weeks.
      • Note that the study did not determine whether the observed lean mass differences lead to improved long-term clinical outcomes.

      Related Resources & Content

      Original Source(s)

      Related Content